AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

The approval is supported by data from the DESTINY-Gastric04 Phase III trial.

Jan 20 (Reuters) - AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.

By Maggie Fick SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on ...

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary Financial performance for 9M 2024 (Growth numbers at constant exchange rates) Pascal Soriot, Chief Executive Officer, ...

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

CNW/ - AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now ...

The company says the proposal will create space for hundreds of its staff to work at the campus.

Saturday through Tuesday: WEATHER ALERT for more dangerous cold and significant snowfall.Highs reach the low 20s Saturday and Sunday with wind chills in the sin Marylanders rush to stock up, leaving ...

AstraZeneca is keeping its options over expansion in Cambridge open by submitting fresh plans for a new conference centre and ...